Ibandronate: pharmacology and preclinical studies

Area of Science:

• Pharmacology
• Bone Biology
• Drug Development

Background:

• Bisphosphonates have evolved with improved antiresorptive potencies over three decades.
• Ibandronate is a potent nitrogen-containing bisphosphonate with high antiresorptive capacity.
• It inhibits farnesyl pyrophosphate synthase, impacting osteoclast activity and binding hydroxyapatite.

Purpose of the Study:

• To investigate the pharmacological efficacy and safety of various continuous and intermittent ibandronate regimens.
• To evaluate ibandronate's effects on bone mass, architecture, strength, and healing in animal models.
• To support the clinical development of intermittent ibandronate for postmenopausal osteoporosis.

Main Methods:

• Experimental models of osteoporosis in rats, dogs, and monkeys were used.
• Ovariectomized (OVX) animal models were treated with intermittent (2, 4, 6 weeks) and continuous ibandronate regimens.
• High doses of ibandronate were administered to assess safety and effects on bone quality and mineralization.

Main Results:

• Intermittent and continuous ibandronate regimens showed equivalent efficacy per total dose in OVX rats, dogs, and monkeys.
• High ibandronate doses were well-tolerated, without impairing bone quality or mineralization in rats.
• Bone mass, architecture, strength, and healing were maintained or improved in animal models.

Conclusions:

• Intermittent ibandronate regimens are effective and safe for managing osteoporosis.
• These findings support the clinical application of intermittent ibandronate for postmenopausal osteoporosis.
• Ibandronate's efficacy is consistent across different dosing schedules and animal models.